COVID-19 Consequences: Takeaways from a Mental Health Survey of US Adults

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

News

Slideshow

Over half of US adults who responded to a new survey said COVID-19 has impacted their mental health. To what extent? Find out in our new slideshow.

In honor of May being National Mental Health Awareness Month, SingleCare recently conducted an online survey of 1000 US adults aged ≥18 years to find out how they are responding psychologically to the current coronavirus disease 2019 (COVID-19) pandemic. In the slides below, you'll find the key takeaways for primary care.

Related Content

Patient Care Staff

January 17th 2025

Respiratory Tripledemic 2022-23: An Expert Recap

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

April 6th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 16th 2025

Distress Signals: How to Help a Clinician Colleague in Need

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

February 14th 2023

Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Grace Halsey

January 15th 2025

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

January 14th 2025

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

Related Content

Patient Care Staff

January 17th 2025

Respiratory Tripledemic 2022-23: An Expert Recap

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

April 6th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 16th 2025

Distress Signals: How to Help a Clinician Colleague in Need

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

February 14th 2023

Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Grace Halsey

January 15th 2025

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

January 14th 2025